Type 2 Diabetes Mellitus Clinical Trial
Official title:
The Effects of Reducing Prolonged Sitting Bouts With Regular Light Upright Movement Breaks on Glucose Regulation in Individuals at High Risk of or With Type 2 Diabetes
Over 3 million in the United Kingdom are now diagnosed with type 2 diabetes, with current
estimates suggesting this will rise to over 5 million by 2025. Type 2 diabetes increases the
risk of developing cardiovascular disease, kidney disease, depression, neuropathy and
dementia, along with being a leading cause of amputation and adult blindness.
Sedentary behaviour, defined as any waking moment spend sitting or reclining with energy
expenditure equal to or less than 1.5 METs, has emerged as a risk factor in the development
of type 2 diabetes. Recent evidence has shown that breaking up prolonged sitting with regular
short bouts of activity or standing lower postprandial glucose and insulin. However, the
effectiveness of breaking prolonged sitting on glucose metabolism over a longer period of
time is unknown. Therefore, the aim of this study is to investigate whether the reduction in
postprandial plasma glucose in response to breaking prolonged sitting time is maintained
following an intervention to reduce and break up prolonged sitting over a four to five week
period.
The study will be a single group intervention with pre and post randomised measurement
conditions (prolonged sitting and light upright breaks) at both time points. A sample of 43
people (34 to complete), aged 50-75, identified as at risk of or with (drug naive) type 2
diabetes will be sought. The intervention will last approximately 5 weeks. Experimental
conditions will be conducted before and after the intervention to assess whether reducing and
breaking up prolonged sitting in free living effects glucose metabolism.
Study Design
This study consists of an intervention lasting approximately 5 weeks (depending on follow-up
measurement timings), with a before and after 'two-arm' randomised crossover design, one
prior to the intervention and one at the end of the intervention used as measurement periods.
Screening will require one laboratory visit, with the study commencing one week following
baseline. The intervention will last a minimum of four weeks, while the measurement
conditions will each involve two laboratory days separated by a minimum of five days. The
duration from screening through to study end will be an estimated 9 weeks. This trial will
evaluate the effectiveness of regular light upright movement breaks at reducing glucose iAUC
by examining if acute adaptations to sitting time are maintained or improved following the
behavioural intervention.
Study Setting
The study will be co-ordinated within the Leicester Biomedical Research Centre (Leicester
Diabetes Centre) at the Leicester General Hospital. Clinical measurement sessions will be
carried out by the appointed research team. Participants will be asked to visit the study
centre on seven occasions.
Measurement conditions
Measurement condition A will consist of seven and a half hours of prolonged sitting, where
participants will be restricted from walking or standing for the duration. Lavatory breaks
will be carried out using a wheelchair to transport the participant to minimise time spent
upright. The condition will be conducted in the laboratory at the Leicester Diabetes Centre.
Participants will have access to a computer with internet services, books and magazines for
the duration of the measurement day.
Upon arrival, the participant will have a cannula inserted into an accessible vein by a
trained member of the study team, which will be used to collect blood samples throughout the
measurement day. Blood pressure will be taken prior to each blood sample, while visual
analogue scales for hunger, energy, fullness, satiety, desire to eat and fatigue will be
completed following each blood sample. The first blood sample will be taken at the start of
the 'steady state' following anthropometric measurements. The next sample will be taken one
hour after the first sample. Following this, participants will be given a standardized meal
consumed over a maximum of 15 minutes. Blood samples will be then be taken at 30, 60, 120 and
180 minutes after commencing eating. Another standardized meal and the same schedule of blood
sampling will take place following the blood sample taken 180 minutes postprandial to the
first meal. Meals will be based on body weight, with eight kcals per kg of body weight, made
up of 52% carbohydrate, 35% fats and 13% protein.
Measurement condition B will follow the same procedures as condition A in terms of
standardised meals, blood sampling, blood pressure, visual analogue scales and meal
consumption. Similarly, participants will be allowed access to a lavatory in the same way as
condition A, as well as have access to a computer, books, magazines and other typical
sedentary pursuits. The only difference in this measurement condition to condition A, is that
participants will regularly break their sitting time, for five minutes every 30 minutes with
upright light movement after sitting quietly for one hour upon arrival and following
cannulation (steady state). This will involve the participant walking and moving around
slowly and freely in the testing room and surrounding laboratory. This is to maximise the
ecological validity of the study, particularly in comparison to studies using a treadmill for
light walking breaks. Five minute breaks every 30 minutes was chosen as this has previously
shown positive effects on both glucose metabolism and insulin in postmenopausal women (19).
Light breaks will accumulate 60 minutes of light upright movement across the measurement day.
Intervention
The participants will be encouraged to reduce prolonged sitting by at least 60 minutes per
day by introducing light upright movement breaks spread throughout their day. The frequency
and duration of these breaks will be tailored to each participant to suit their individual
circumstances. A 60 minute reduction is judged to be clinically meaningful. For example, a
modelling study found that replacing 60 minutes of sedentary time with light movement was
associated with around 20% better insulin sensitivity in those with dysglycemia.
The intervention will involve one participant face-to-face session, lasting approximately two
hours. It will also involve personalised feedback which will review progress and goals based
on the baseline data. The visit will involve personalised education and goal setting, based
on objective measures of sitting time taken at baseline. These data will be explained to the
participant, which will then form the basis of a plan to reduce prolonged bouts of sitting
with light movement. This session will also explain what is meant by light movement, as well
as identifying a number of different ways to break prolonged bouts effectively. Participants
will be encouraged to self-monitor their sitting time, with specific examples of how his can
be achieved depending on the needs of the participant. They will be given an accelerometer to
be worn for the duration of the four week intervention.
The participant will receive feedback from a member of the study team on at least a weekly
basis (more frequently feedback expected in the early weeks) in regards to current sedentary
behavior and movement time. Data received from the accelerometer or self-monitoring device
will be used to discuss the positives and negatives of the previous days or week's behaviour.
These will be talked through and adjustments made to the goals if needed. The feedback
sessions will take place primarily over the telephone, however if the participant would like
to visit the Leicester Diabetes Centre for these sessions that will be made available to
them. All feedback is personalised meaning it will be different for each participant in terms
of the data fed back as well as the timings of each feedback session
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02252224 -
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
|